277 related articles for article (PubMed ID: 30962720)
1. A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of
Forbes C; Fayter D; de Kock S; Quek RG
Cancer Manag Res; 2019; 11():2321-2337. PubMed ID: 30962720
[TBL] [Abstract][Full Text] [Related]
2. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.
Tung NM; Boughey JC; Pierce LJ; Robson ME; Bedrosian I; Dietz JR; Dragun A; Gelpi JB; Hofstatter EW; Isaacs CJ; Jatoi I; Kennedy E; Litton JK; Mayr NA; Qamar RD; Trombetta MG; Harvey BE; Somerfield MR; Zakalik D
J Clin Oncol; 2020 Jun; 38(18):2080-2106. PubMed ID: 32243226
[TBL] [Abstract][Full Text] [Related]
3. PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.
Taylor AM; Chan DLH; Tio M; Patil SM; Traina TA; Robson ME; Khasraw M
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011395. PubMed ID: 33886122
[TBL] [Abstract][Full Text] [Related]
4. Survey on implementation of molecular testing in ovarian cancer and PARP inhibitor: a national North-Eastern German Society of Gynecologic Oncology/Young Academy of Gynecologic Oncology/Arbeitsgemeinschaft Gynäkologische Onkologie intergroup analysis.
Nguyen-Sträuli BD; Baum J; Meyer-Wilmes P; Kreklau A; Buschmann C; El Ouardi N; Fotopoulou C; Hummel M; Chekerov R; Braicu E; Sehouli J; Pietzner K
Int J Gynecol Cancer; 2022 Jul; ():. PubMed ID: 35896275
[TBL] [Abstract][Full Text] [Related]
5. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
6. Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer: Overcoming Challenges in Genetic Testing and Clinical Considerations When Using Talazoparib.
Brugioni E; Cathcart-Rake E; Metsker J; Gustafson E; Douglass L; Pluard TJ
Clin Breast Cancer; 2023 Jul; 23(5):469-477. PubMed ID: 37246120
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology.
Miglietta F; Cinquini M; Dieci MV; Cortesi L; Criscitiello C; Montemurro F; Del Mastro L; Zambelli A; Biganzoli L; Levaggi A; Delle Piane C; Marchiò C; Calabrese M; Fortunato L; Franco P; Meduri B; Fittipaldo VA; Gori S
Breast; 2022 Dec; 66():293-304. PubMed ID: 36379199
[TBL] [Abstract][Full Text] [Related]
9. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers.
Grindedal EM; Heramb C; Karsrud I; Ariansen SL; Mæhle L; Undlien DE; Norum J; Schlichting E
BMC Cancer; 2017 Jun; 17(1):438. PubMed ID: 28637432
[TBL] [Abstract][Full Text] [Related]
10. All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits.
Wu HL; Luo ZY; He ZL; Gong Y; Mo M; Ming WK; Liu GY
Br J Cancer; 2023 Feb; 128(4):638-646. PubMed ID: 36564566
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.
O'Shaughnessy J; Brezden-Masley C; Cazzaniga M; Dalvi T; Walker G; Bennett J; Ohsumi S
Breast Cancer Res; 2020 Oct; 22(1):114. PubMed ID: 33109210
[TBL] [Abstract][Full Text] [Related]
12. An Overview of PARP Inhibitors for the Treatment of Breast Cancer.
Cortesi L; Rugo HS; Jackisch C
Target Oncol; 2021 May; 16(3):255-282. PubMed ID: 33710534
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of the international prevalence of
Armstrong N; Ryder S; Forbes C; Ross J; Quek RG
Clin Epidemiol; 2019; 11():543-561. PubMed ID: 31372057
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
[TBL] [Abstract][Full Text] [Related]
15. Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.
Eccles DM; Balmaña J; Clune J; Ehlken B; Gohlke A; Hirst C; Potter D; Schroeder C; Tyczynski JE; Gomez Garcia EB
Adv Ther; 2016 Feb; 33(2):129-50. PubMed ID: 26809252
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review.
Sun X; Wang X; Zhang J; Zhao Z; Feng X; Liu L; Ma Z
Breast; 2021 Dec; 60():26-34. PubMed ID: 34455227
[TBL] [Abstract][Full Text] [Related]
17. Ovarian cancer risk management in BRCA-mutation carriers: A comparison of six international and national guidelines.
Matan LS; Perri T; Kogan L; Brandt B; Meyer R; Levin G
Eur J Obstet Gynecol Reprod Biol; 2022 Nov; 278():166-171. PubMed ID: 36208522
[TBL] [Abstract][Full Text] [Related]
18. The first Japanese nationwide multicenter study of
Enomoto T; Aoki D; Hattori K; Jinushi M; Kigawa J; Takeshima N; Tsuda H; Watanabe Y; Yoshihara K; Sugiyama T
Int J Gynecol Cancer; 2019 Jul; 29(6):1043-1049. PubMed ID: 31263023
[TBL] [Abstract][Full Text] [Related]
19. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
